Richmond Pharmacology has globally recognised expertise in cardiac safety, intensive ECG studies, cardiology overreading, statistical analysis, reporting and publishing.
We are proud of our successful track record which is demonstrated in our published studies.
We provide sponsors with FDA compliant analysis methods, and the option to include a non-pharmacological method of proving assay sensitivity. Our unique and innovative approach means that we conduct our studies and prove assay sensitivity as a standard feature. This has provided quality data in many Japanese bridging, SAD and MAD studies, eliminating the need for a dedicated TQT study.
Food effect on QT interval. Our research has confirmed food impacts cardiac repolarisation by shortening the J-T peak. This can be used in our studies as a non-pharmacological method of proving assay sensitivity. Learn more here.
Sex hormones and the QT Interval. Research funded by Richmond Pharmacology identified a significant influence of estradiol on QTcF suggesting a menstrual cycle could influence the QTc. Learn more here.
Our study data is well respected by regulators such as FDA, EMA and PMDA. Our statistical team specialise in statistical analysis concentration effect modelling, reporting, and publishing.
Our core ECG laboratory provides a centralised system for all our studies.
We undertake and analyse several cardiological assessments using state-of-the-art equipment.
Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London.
Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.
We are on the lookout for people who love what they do, strive for excellence and who want to make a difference.